Welcome to our dedicated page for Inspiremd SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InspireMD, Inc. (NSPR) files reports with the U.S. Securities and Exchange Commission as a Nasdaq-listed medical device company focused on the CGuard® Prime carotid stent system and its proprietary MicroNet™ mesh technology. These SEC filings provide detailed information on the company’s financial condition, capital structure, clinical and regulatory milestones, and governance.
Current reports on Form 8-K frequently disclose key events such as quarterly financial results, private placement financings, warrant exercises, and updates to investor presentations. For example, a November 4, 2025 Form 8-K discusses financial and operating results for the quarter ended September 30, 2025, while a July 31, 2025 Form 8-K outlines a securities purchase agreement for a private placement of common stock and pre-funded warrants, as well as the full exercise of a series of warrants.
Filings also document important regulatory and commercial milestones. A June 24, 2025 Form 8-K reports that InspireMD received FDA premarket approval (PMA) for the CGuard Prime Carotid Stent System in the United States, and a July 9, 2025 Form 8-K references a press release announcing the U.S. commercial launch of CGuard® Prime. Other 8-Ks describe changes to the board of directors, including the appointment of independent directors and audit committee chairs, and amendments that specify committee assignments.
On this page, users can review InspireMD’s Forms 8-K and related exhibits, along with other periodic reports when available. Stock Titan adds AI-powered summaries that explain the main points of lengthy filings, highlight material agreements and capital-raising terms, and surface notable disclosures about clinical and regulatory developments. Investors and researchers can use these NSPR filings to understand how InspireMD reports its progress in carotid stenting, manages its capital resources, and addresses the risks and uncertainties outlined in its forward-looking statements.
InspireMD, Inc. director Scott R. Ward reported an equity award of common stock. On January 14, 2026, he received 88,053 shares of common stock at a price of $0 per share, characterized as an acquisition. These shares are restricted stock that will vest on January 14, 2027, as long as he continues in service with the company through that date. Following this grant, he beneficially owns 147,846 shares of InspireMD common stock directly.
InspireMD, Inc. reported that Chief Operating Officer Andrea Tommasoli received an award of 226,695 shares of common stock on January 14, 2026. The shares were acquired at a price of $0 per share, indicating a grant of restricted stock rather than an open-market purchase. Following this grant, Tommasoli beneficially owned 954,389 shares of InspireMD common stock directly.
According to the footnote, these shares are restricted stock that vest in three equal annual installments, with one-third scheduled to vest on each of January 14, 2027, January 14, 2028 and January 14, 2028, subject to Tommasoli’s continued service with the company. This structure ties a portion of the executive’s compensation to ongoing employment and future share value.
InspireMD, Inc. director Paul Stuka reported a grant of 132,076 shares of common stock as restricted stock on January 14, 2026. The award was reported at a price of $0 per share and will vest on January 14, 2027, provided he continues to serve, bringing his directly held common shares to 523,704.
The filing also notes 444,195 shares of InspireMD common stock held indirectly through Osiris Investment Partners, L.P. Mr. Stuka is the managing member of the general partner of Osiris and may be deemed to beneficially own these securities, but he disclaims beneficial ownership except to the extent of his pecuniary interest. No transaction occurred with respect to these Osiris-held shares; they are reported for informational purposes.
InspireMD, Inc. reported an equity award to its CEO and President, Marvin Slosman, in the form of 1,114,792 restricted stock units granted on January 14, 2026 at a price of $0 per unit. After this grant, he beneficially owns 3,535,658 InspireMD shares. These restricted stock units vest in three equal annual installments, with one-third vesting on each of January 14, 2027, January 14, 2028, and January 14, 2029, as long as he continues in service with the company.
InspireMD, Inc. director receives restricted stock grant. Director Gary S. Roubin reported an award of 88,053 shares of InspireMD common stock on January 14, 2026. The shares were acquired at a stated price of $0 per share as a stock award, increasing his beneficial ownership to 744,478 common shares held directly. The 88,053 shares are restricted stock that will vest on January 14, 2027, provided he continues to serve through that one-year grant anniversary date.
InspireMD, Inc. reported an equity grant to its Chief Financial Officer. A Form 4 shows CFO Michael Lawless received an award of 226,695 shares of common stock on January 14, 2026 at a price of $0 per share, increasing his directly held stake to 691,695 shares.
The new shares are restricted stock that vest in three equal annual installments, with one-third vesting on each of January 14, 2027, January 14, 2028, and January 14, 2029, as long as he continues in service with the company.
InspireMD, Inc. reported that Chief Commercial Officer Shane Gleason received an award of 453,390 shares of common stock on January 14, 2026 at a price of $0 per share.
These shares are restricted stock that vest in three equal annual installments on January 14, 2027, January 14, 2028 and January 14, 2029, conditioned on his continued service. After this grant, he directly beneficially owns 1,200,371 shares of InspireMD common stock.
InspireMD, Inc. director Danny L. Dearen reported a stock award of 44,030 shares of common stock on January 14, 2026. The Form 4 shows the shares were acquired at a price of $0 per share as a grant of restricted stock.
According to the footnote, these 44,030 shares are restricted stock that will vest on January 14, 2027, the one-year grant anniversary date, subject to his continued service. Following this grant, Dearen beneficially owns 102,047 shares of InspireMD common stock in direct ownership.
InspireMD, Inc. director Raymond W. Cohen reported receiving 44,030 shares of common stock on January 14, 2026 as an award of restricted stock. The shares were granted at a reported price of $0 per share, indicating an equity compensation grant rather than an open‑market purchase.
According to the filing, these restricted shares are scheduled to vest on January 14, 2027, subject to his continued service. After this grant, Cohen beneficially owned 92,417 shares of InspireMD common stock in direct ownership.
InspireMD, Inc. director Michael Berman reported an equity grant of common stock. On January 14, 2026, he received 88,053 shares of restricted common stock at a price of $0 per share, increasing his directly held beneficial ownership to 352,586 common shares.
The filing explains that these 88,053 shares are restricted stock that will vest on January 14, 2027, as long as he continues in service through that date. It also lists an additional 244,994 common shares as indirectly held through the Michael Berman Revocable Trust, with no transaction in those trust-held securities; they are included for informational reporting only.